Grace Therapeutics Narrows Losses but Faces FDA Hurdles for GTx-104 Approval

Event summary

  • Grace Therapeutics reported a net loss of $7.8 million for fiscal 2026, a $1.8 million improvement from the prior year.
  • The FDA issued a Complete Response Letter (CRL) for GTx-104 in April 2026, citing issues in Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections.
  • Phase 3 STRIVE-ON trial results were presented at multiple medical conferences, showing a 19% reduction in clinically significant hypotension with GTx-104 compared to oral nimodipine.
  • The company has $17.0 million in cash and cash equivalents as of March 31, 2026, with a runway of at least 12 months.

The big picture

Grace Therapeutics is navigating a critical juncture with its lead candidate GTx-104, facing FDA hurdles that could delay approval. The company's financials show improved cost management, but the path to commercialization hinges on resolving regulatory deficiencies. The biopharma sector is closely watching how Grace Therapeutics handles these challenges, as successful resolution could position GTx-104 as a significant innovation in treating aneurysmal subarachnoid hemorrhage (aSAH).

What we're watching

Regulatory Pathway
The outcome of the Type A meeting with the FDA will determine the clarity and feasibility of resubmitting the NDA for GTx-104.
Financial Sustainability
Whether Grace Therapeutics can extend its cash runway beyond 12 months while addressing the FDA's CRL requirements.
Market Adoption
The pace at which medical conferences and industry leaders embrace GTx-104 data could influence its commercial potential.